Quality is beyond debate, valuations are not
17/11/26 -"In the last couple of years, most of Roche’s peers – including Novartis, AstraZeneca, Novo Nordisk and Sanofi – have suffered important R&D setbacks, whereas the Swiss giant has avoided major ..."
Pages
69
Language
English
Published on
17/11/26
You may also be interested by these reports :
17/11/26
In the last couple of years, most of Roche’s peers – including Novartis, AstraZeneca, Novo Nordisk and Sanofi – have suffered important R&D setbacks, ...
17/11/26
The factors discussed in the justification for DCF valuation have also prompted an upgrade to our NAV valuation. As a result, the target price resets ...
12/11/26
The Q3 results exceeded consensus estimates, backed by the strong showing of Electronics (driven by demand from AI applications) and healthy support ...
11/11/26
The Q3 profitability materially surpassed expectations, backed by the strong momentum for migraine and depression/schizophrenia treatments. The ...